Litcius/Paper detail

Continued Refinement of the Treatment for Light-Chain Cardiac Amyloidosis

Justin L. Grodin, Larry D. Anderson, Ankit Kansagra

2021Circulation65 citationsDOIOpen Access PDF

Abstract

ight chain cardiac amyloidosis (AL-CA) is a devastating disease caused by a buildup of abnormal, misfolded light chain aggregates in the myocardium. When untreated, AL-CA leads to progressive heart failure and premature death. The long-term prognosis of AL-CA is dependent on the disease stage at diagnosis and then the response to treatment. Median survival of advanced stage AL-CA at diagnosis may approximate 6 months. 1 These sobering metrics have served to motivate the detection of AL-CA in earlier stages and the continued advancements of treatment for AL-CA.

Topics & Concepts

MedicineCardiac amyloidosisAmyloidosisCardiologyDiseaseHeart failureAL amyloidosisStage (stratigraphy)Internal medicineCardiac imagingHeart diseaseRare diseaseCardiomyopathyProgressive diseaseAmyloid (mycology)Amyloidosis: Diagnosis, Treatment, OutcomesEosinophilic Disorders and SyndromesParathyroid Disorders and Treatments